Biodesix Inc (BDSX)
Biodesix, Inc. is a diagnostic solutions company listed on the NASDAQ under the ticker BDSX. The company develops blood-based testing for lung nodules and lung cancer, including the Nodify XL2 and Nodify CDT tests, which are used in its Nodify Lung Nodule Risk Assessment offering to help evaluate malignancy risk and support treatment-pathway decisions. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests within its IQLung testing strategy to aid in lung cancer diagnosis and treatment selection by assessing tumor mutations and the patient’s immune response. Beyond its clinical tests, Biodesix offers a range of diagnostic and research support services for biopharmaceutical, life sciences, and diagnostic companies, including biomarker discovery, assay development, clinical trial sample testing, regulatory support, and commercialization services. The company also operates laboratories. Biodesix was incorporated in 2005, changed its name from Elston Technologies, Inc. in 2006, and is headquartered in Louisville, Colorado.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BDSX
|
$20.80
|
-26.1% Downside
|
Overvalued
|
$34
|
20.8% Upside
|
Undervalued
|
Good
|
0.0%
|
October 30, 2026
|
32.8x
|
2.9x
|
297 M
|
341.8 M
|
19.3%
|
47.2%
|
-6.3
|
72.9%
|
